Alpha Cognition 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Alpha Cognition reported Q3 2026 net product revenues of approximately $7.8 million, up approximately 30% sequentially from approximately $6 million in Q2 2026 and more than 230% from $2.3 million in Q3 2025.
- The company said more than 30,000 prescriptions had been filled for Zumbill across 6 quarters of commercialization; Q3 included over 11,000 filled prescriptions, which Lauren D'Angelo said increased approximately 40% quarter over quarter.
- GAAP gross product margin was approximately 94%, consistent with the prior quarter, while total operating expenses were $13.7 million, including roughly $12.4 million of SG&A and $1.3 million of R&D.
- Alpha Cognition reported a Q3 operating loss of $6.4 million and a net loss of $7.6 million, or $0.35 per share, compared with a Q2 net loss of $8.2 million, or $0.38 per share.
- At September 30th, 2026, the company had $37.8 million in cash and cash equivalents, compared with $41.4 million at June 30th, 2026, and remained debt-free; cash declined approximately $3.6 million, including approximately $1.4 million of proceeds from warrant and stock option exercises.
- HCP writers grew 23% sequentially to 1,654, cumulative writers reached 2,438, and the number of homes with Zumbill prescriptions grew 29% sequentially to 1,400; 78% of prescribers placed repeat prescriptions and productivity rose to approximately 7 prescriptions per writer from approximately 6 in Q2.
- CONVERGE data showed approximately 80% of Zumbill residents who were new to acetylcholinesterase inhibitor therapy or switched from a competitor reached a therapeutic dose within 180 days, which management said was statistically superior to all other drugs in the therapeutic class.
- In CONVERGE, Zumbill residents discontinued an average of 2 medication classes, with a net decrease across all 8 classes evaluated; residents on generic acetylcholinesterase inhibitors added 2 more medication classes than they discontinued.
- The company completed and presented 11 BEACON abstracts at medical meetings, while RESOLVE continued enrollment with over 57 patients enrolled.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
As a reminder, this conference is being recorded. It is now my pleasure to introduce Henry Du, Interim CFO and VP of Accounting and Finance. Henry, please go ahead. Thank you, Joe.
Good afternoon, everyone, and thank you for joining us today for Alpha Cognition's third quarter 2026 financial results conference call. Today, after the close of market, the company issued a press release announcing these results. On the call with me today are Alpha Cognition's Chief Executive Officer, Michael McFadden, and Chief Operating Officer, Lauren D'Angelo. Today's call is being made available via the Investors section of the company's website at www.alphacognition.com. During the course of this call, management may make certain forward-looking statements regarding the future events and the company's future performance. These forward-looking statements reflect Alpha Cognition's current perspective on existing trends and information. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in the risk factor section of the company's latest SEC filings. Actual results may differ materially from those projected in these forward-looking statements.
For the benefit of those of you who may be listening to the replay, this call is being held and recorded on November 11th, 2026. Since then, the company may have made additional announcements related to the topics discussed. Please reference the company's most recent press releases and current filings with the SEC. Alpha Cognition declines any obligation to update these forward-looking statements, except as required by applicable securities laws. I'll now turn the call over to Michael.
Michael? Thank you, Henry. Good afternoon, everyone.
Welcome to today's call. The third quarter of 2026 was our strongest quarter since the launch of ZUNVEYL, the first new oral Alzheimer's treatment approved in more than a decade. We delivered accelerating demand and record prescriber and facility adoption while holding our operating spend essentially flat with the second quarter. This growth, in combination with disciplined operating spend, aligns with our goal of achieving operating profitability in 2027. During this call, we'll emphasize four primary things. ZUNVEYL's growth is accelerating. Growth achieved on better targeted calls. Financial stewardship remains on track for operating profitability in 2027. We'll highlight real-world evidence for ZUNVEYL as it continues to strengthen positioning and differentiation. In Q3, we generated net product revenues of approximately $7.8 million, representing approximately 30% sequential growth over Q2 2026. Filled prescriptions for the quarter were up approximately 31% quarter-over-quarter.
More than 30,000 prescriptions have been filled for ZUNVEYL across six quarters of commercialization. We're pleased by the growth underlying these numbers with HCP writers, cumulative writers since launch, and homes with ZUNVEYL prescriptions, all reaching or exceeding our expectations for the quarter. Lauren D'Angelo will provide more color on the KPIs and our commercial progress in a moment, but I'll share that management is pleased with our KPI attainment at this point in the year. Turning to our clinical and medical programs, we're continuing to read out real data in the setting where these patients are actually treated. We believe the data the company is generating will help us in discussions with our long-term care practitioners and with payers. Let me start with CONVERGE. On October 1st, we announced first results from CONVERGE, a retrospective real-world evidence program using longitudinal long-term care data. I want to highlight two things.
The first was titration data. Among residents who were new to acetylcholinesterase inhibitor therapy or switched from a competitor, approximately 80% of ZUNVEYL residents reached a therapeutic dose within 180 days. This is statistically superior to all other drugs in the therapeutic class. For three decades, the single biggest practical failure of this drug class in nursing homes has been that patients never get to an effective dose because they cannot tolerate the older medications. So I'm very pleased by what this data represents about the potential for ZUNVEYL to make a difference. The second is polypharmacy. ZUNVEYL residents on average discontinued two medication classes, producing a net decrease across all eight medication classes evaluated. This included antipsychotics, other psychotropics, gastrointestinal medications, and sleep medications. Residents on generic acetylcholinesterase inhibitors did the opposite.
They added two more medication classes than they discontinued, with net increases across the same eight medication classes just listed. Now, in a setting where polypharmacy drives cost, staff burden, CMS quality measures, we believe this data will resonate with both our nursing home providers, the nursing homes themselves and their staff, and with payers. CONVERGE remains ongoing. We expect additional dataset updates in January and also in March, which should expand the number of ZUNVEYL residents available for analysis, and we expect to publish data from CONVERGE starting in the first half of 2027. Turning to BEACON. We completed and presented 11 abstracts at medical meetings. The analysis spanned cognition, activities of daily living, neuropsychiatric symptoms, tolerability, treatment patterns, and psychotropic medication utilization. This data is now available for medical professionals on the Alpha Cognition website under the Medical Affairs tab.
RESOLVE, our interventional study in patients with behavioral symptoms, continues to enroll, with over 57 patients enrolled. We continue to anticipate study completion in the second half of 2027, and we'll provide top-line data when that study completes. On the development side, we're continuing to do work with our sublingual program. Our PK study concluded in early October, and the data was inconclusive from this study. The company believes we can resolve this with an additional study, which we're initiating in early January. Our partner, CMS Pharma, we continue to work through the regulatory processes in Asia, where we anticipate approvals in two countries in the near term. We responded to the Chinese regulatory authorities on their questions and inquiries about the program, and we await any additional questions they may have.
On the intellectual property front, in October, we announced that the U.S. Patent and Trademark Office published our patent application covering proprietary manufacturing processes for benzgalantamine. Additionally, we had the benzgalantamine polymorph patent approved in Hong Kong and Russia during the quarter. This further strengthens patent protection for benzgalantamine in the U.S. market and around the world, and the company anticipates additional patent approvals in the coming weeks and quarters. With that, I'll turn the call over to Lauren to discuss our commercial progress.
Lauren. Thank you, Michael. This was our strongest quarter since launch, with continued demand growth and meaningful improvement in commercial productivity.
Q3 generated approximately $7.8 million in net product sales, up 30% sequentially, driven by over 11,000 filled prescriptions, an increase of approximately 40% quarter-over-quarter. Net revenue per prescription remained essentially stable at approximately $650 per bottle, demonstrating that growth was driven by prescription volume rather than price. Just as importantly, we are becoming more productive in how we generate that demand. During Q3, our commercial team made over 7,000 calls and reached roughly 3,400 targeted prescribers. We continue to refine both who we call on and the frequency of engagement, and we are seeing the impact of that increased focus. The number of HCP writers grew 23% sequentially to 1,654, with cumulative writers reaching 2,438.
More than half of the prescribers we called on wrote ZUNVEYL during Q3, compared with approximately 35% in Q2. At 2,438 cumulative writers launched to date, we have already surpassed our original full-year goal of approximately 2,000 prescribers with one quarter remaining and remain on track to exceed our revised goal of 2,500. Importantly, we are not simply adding writers. We are seeing greater depth within our existing prescriber base. Approximately 78% of prescribers placed repeat prescriptions, while productivity increased to approximately seven prescriptions per writer, up from approximately six in Q2. We are seeing similar momentum at the facility level. We called on approximately 2,800 nursing homes during the quarter, and the number of homes with a ZUNVEYL prescription grew 29% sequentially to 1,400, with approximately 80% of those homes placing repeat orders. Cumulatively, we have now reached 1,900 ordering homes, with 81% placing repeat orders.
Expansion continued through quarter end, including 103 new ordering homes in September alone. We are pleased that a significant and growing part of our business now comes from the psychiatry channel, including psychiatrists, nurse practitioners, and physician assistants practicing in long-term care. Turning to payer access, we continue to see encouraging progress. Where our reimbursement team supports the prior authorization process, approximately 95% of prescriptions are approved, and approximately 70% of long-term care lives have access to ZUNVEYL with a $0 copay. What is particularly encouraging to us is that we achieved strong sequential prescription growth in Q3 without a meaningful change in formulary access. As broader contracted access is implemented downstream, we believe payer access can become an additional driver of growth. As Michael discussed, our real-world evidence program is also beginning to support our commercial efforts in a very practical way.
One of the most common questions our representatives have heard since launch is whether frail long-term care residents can successfully be titrated to an effective dose. The CONVERGE data provide real-world evidence addressing that question and give our commercial team additional evidence to support conversations with healthcare professionals. Stepping back, Q3 demonstrated progress across the key areas we have been focused on: accelerating demand, improving commercial productivity, expanding and deepening our prescriber base, increasing facility penetration, and advancing payer access. We exceeded our original full-year prescriber goal a quarter early and remain on pace to exceed our home goal. With increasing depth among existing prescribers and facilities, continued customer expansion, and further payer access ahead of us, we believe ZUNVEYL enters the fourth quarter from a position of increasing commercial strength. I will now turn it over to Henry to discuss the financials in greater detail.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
